

Tate & Lyle PLC

25 March 2004 – Trading Update prior to entering closed period

Before entering its closed period for the year ending 31 March 2004 and prior to meeting with stockbrokers' analysts, Tate & Lyle issues the following routine trading update. The preliminary announcement of results for the year ending 31 March 2004 will be made on 3 June 2004. Since the update on 28 January 2004 Tate & Lyle's overall trading has remained in line with our expectations with Staley performing slightly better and Amylum slightly worse. Our outlook for 2005 remains unchanged.

The annual sweetener pricing round in the US is now essentially complete with outcomes within our forecast range. Our sugar operations in Europe, Canada and Mexico continue to perform in line with expectations and generate strong cash flow for the Group. Whilst, as expected, a working capital cash outflow is forecast for the financial year (in part due to higher raw material prices), net debt is expected to benefit from exchange translation.

The realignment of the sucralose agreements with McNeil Nutritionals and the acquisition of the sucralose manufacturing plant and ingredients business by Tate & Lyle (announced on 19 February 2004) remains on track for completion in early April 2004.

For more information contact Tate & Lyle PLC:

Mark Robinson, Head of Investor Relations
Tel: +44(0)20 7626 6525 or Mobile: +44(0)7793 515 861
Email: investorrelations@tateandlyle.com

Chris Fox, Director of Corporate Relations (Press)
Tel: +44(0)20 7626 6525 or Mobile: +44(0)7801 808553

About Tate & Lyle

Tate & Lyle is a world leader in renewable ingredients. Its core competence is to take corn, wheat or sugar, and add value to these raw materials through technology. As a result of continuous innovation it offers an ever-wider product portfolio of versatile and functional ingredients. These products include Cereal Sweeteners, Starches, Sugars, Citric Acid and SPLENDA® Sucralose. Tate & Lyle products have wide applications in the food, beverage, pharmaceutical, cosmetic, paper, packaging and building industries.

With headquarters in London, Tate & Lyle operates more than 41 plants and 20 additional production facilities in 28 countries, almost all in Europe and the Americas. It employs 6,700 people in its subsidiaries with a further 4,800 employed in joint ventures. Sales in the year to 31 March 2004 totalled £3,167 million. More details are available on this website www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC